Dylan Morris

Dylan Morris has worked in a variety of roles since 2018. In 2021, they became a Managing Director at Insight Partners, a Board Director at ArrePath, and a Board Observer at NanoMosaic Inc. In 2022, they will become a Board Director at DEM Biopharma, Inc., Unlearn.AI, and Gameto. Prior to that, they were a Board Director at Dyno Therapeutics from 2018, a Board Director at Switch Therapeutics from 2020, a Board Director at Deciduous Therapeutics from 2019, and a Board Observer at Exo Therapeutics from 2019.

Dylan Morris is currently pursuing a Graduate Research degree in Biochemistry and Molecular Biophysics at Caltech. Dylan previously obtained an AB in Computer Science from Harvard University.